Exosome-mediated Delivery of SCD-1 SiRNA Promoted the Death of Anaplastic Thyroid Carcinoma Cells Via Regulating ROS Level
Overview
Affiliations
Purpose: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive cancers in the world. Stearoyl-CoA desaturase-1 (SCD-1) is one of major enzymes in the de novo synthesis of fatty acids and is related to cancer aggressiveness and poor patient prognosis. The study aimed to construct exosomes loaded SCD-1 interference, investigate its effects and mechanisms on the cell proliferation and apoptosis of ATC cells.
Methods: The expressions of SCD-1 in normal thyroid cell line and ATC cell lines were determined by qRT-PCR and western blotting, respectively. Exosomes were prepared and purification then loaded with SCD-1 siRNA by electroporation and observed by transmission electron microscopy. Higher SCD-1 mRNA and protein levels were found in ATC cell lines compared than normal thyroid cell line (P < 0.05), and both Hth-7 and FRO cells could uptake PKH67-labeled exosomes. The effects of exosomes loaded SCD-1 siRNA on ATC cells were measured by CCK8 assay and apoptosis detection kit.
Results: When compared with control group, the cell viability significantly decreased in both two ATC cell lines taken up exosomes loaded SCD-1 siRNA (P < 0.001), and apoptotic and necrotic cells obviously increased (P < 0.05). In order to explore the mechanism of exosomes loaded SCD-1 on ATC, the ROS level was detected by fluorescence reagent. It was found that exosomes loaded SCD-1 siRNA significantly increased intracellular ROS level of ATC cells (P < 0.05).
Conclusions: Exosomes loaded SCD-1 siRNA inhibited ATC cellular proliferation and promoted cellular apoptosis, and the mechanisms involved maybe the regulation of fatty acids metabolism and ROS level. Our study provides a promising therapeutic strategy for ATC.
Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.
Wan Y, Li G, Cui G, Duan S, Chang S Mol Cancer. 2025; 24(1):74.
PMID: 40069775 PMC: 11895238. DOI: 10.1186/s12943-025-02263-4.
Exploring exosomes: novel diagnostic and therapeutic frontiers in thyroid cancer.
Zhang S, Yang Y, Wang D, Yang X, Cai Y, Shui C Front Pharmacol. 2024; 15:1431581.
PMID: 39584141 PMC: 11581896. DOI: 10.3389/fphar.2024.1431581.
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.
Ubanako P, Mirza S, Ruff P, Penny C Front Mol Biosci. 2024; 11:1447953.
PMID: 39355533 PMC: 11442288. DOI: 10.3389/fmolb.2024.1447953.
Liu J, Bai Y, Li Y, Li X, Luo K EBioMedicine. 2024; 107:105301.
PMID: 39178747 PMC: 11388279. DOI: 10.1016/j.ebiom.2024.105301.
Exosomal noncoding RNAs: decoding their role in thyroid cancer progression.
Sun W, Jiang C, Liu Q, Wang N, Huang R, Jiang G Front Endocrinol (Lausanne). 2024; 15:1337226.
PMID: 38933820 PMC: 11199389. DOI: 10.3389/fendo.2024.1337226.